Bristol-Myers Squibb (BMS) has expanded its strategic collaboration with CytomX Therapeutics to discover novel therapies that will include up to eight additional oncology and non-oncology targets using CytomX’s proprietary Probody™ antibody platform. The original agreement was signed in 2014 for the development of Probodies for up to four oncology targets. The deal comes at a critical time following a number of major setbacks with BMS’s top-selling immuno-oncology drug, Opdivo® (nivolumab).